Publications by authors named "A Rabeau"
Article Synopsis
- * It introduces modern analysis techniques that factor in the timing and recurrence of immune-related AEs (irAEs) in cancer patients treated with immune checkpoint inhibitors, based on the MOTIVATE prospective study findings.
- * Results showed variations in the prevalence and timing of irAEs between melanoma and non-small cell lung cancer (NSCLC) patients, leading to more comprehensive safety assessments that can guide clinical and regulatory decisions.
Introduction: Myocarditis is the most lethal cardiovascular immune related adverse events with a low incidence, depending on the studies. We prospectively studied the potential interest of a systematic screening to early detect immune related myocarditis and confirm the incidence of immune-induced myocarditis in advanced lung cancer and the impact of troponin systematic screening in early detection of other major cardiovascular events (MACE).
Material And Methods: This prospective bicentric study includes adults who received at least one dose of immune checkpoint inhibitor (ICI) for advanced lung cancer.
Article Synopsis
- The text discusses a rare case of bacteremia caused by a strain of an anaerobic, spore-forming Gram-positive bacterium associated with severe infections like necrotizing gangrene and gastrointestinal issues.
- In 2014, a new toxin called BEC was identified, which can lead to acute gastroenteritis in humans; the text highlights a 64-year-old man who developed pneumonia and septic shock, ultimately passing away despite treatment.
- Whole genome sequencing of the bacteria found in the patient revealed various virulence factors, including the newly discovered BEC toxin, and confirmed a significant genetic diversity among BEC-producing strains.
Background: The optimal modalities of radiotherapy when combining concurrent chemoradiation (CCRT) and immunotherapy (IO) for locally advanced non-small cell lung cancer (LA-NSCLC) remain to be determined. The aim of this study was to investigate the impact of radiation on different immune structures and immune cells in patients treated with CCRT followed by durvalumab.
Material And Methods: Clinicopathologic data, pre- and post-treatment blood counts, and dosimetric data were collected in patients treated with CCRT and durvalumab consolidation for LA-NSCLC.